Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
There's no money to replace most of NC students' laptops. What are schools doing about it?
Recommended
Cyclospora parasite illnesses have affected 28 NC counties, sickened more than 200 people
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by HOOKIPA Pharma Inc.
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
July 22, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
ARVN
HOOK
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
July 08, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
July 01, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
June 04, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
May 30, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
May 23, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
April 25, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
April 24, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
April 10, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 22, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
March 06, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
January 29, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
January 16, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
December 21, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
November 20, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
November 03, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023
November 02, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
October 22, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
October 18, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Announces Executive Leadership Change
September 13, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma to participate in upcoming investor conferences in September
September 06, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 10, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023
August 03, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
May 31, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tickers
HOOK
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.